Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 249867, 6 pages
http://dx.doi.org/10.1155/2011/249867
Review Article

Factors Affecting the Cost Effectiveness of Antibiotics

Research Centre for Pharmaceutical Care and Pharmaco-Economics, Katholieke Universiteit Leuven, Onderwijs en Navorsing 2, P.O. Box 521, Herestraat 49, 3000 Leuven, Belgium

Received 29 October 2010; Accepted 5 January 2011

Academic Editor: Enzo Bonmassar

Copyright © 2011 Steven Simoens. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Feldman, “Appropriate management of lower respiratory tract infections in primary care,” Primary Care Respiratory Journal, vol. 13, no. 3, pp. 159–166, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. Woodhead, F. Blasi, and F. Blasi, “Guidelines for the management of adult lower respiratory tract infections,” European Respiratory Journal, vol. 26, pp. 1138–1180, 2005. View at Google Scholar
  3. L. A. Mandell, R. G. Wunderink, and R. G. Wunderink, “Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults,” Clinical Infectious Diseases, vol. 44, no. 2, pp. S27–S72, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. B. Wasserfallen, F. Livio, and G. Zanetti, “Acute rhinosinusitis: a pharmacoeconomic review of antibacterial use,” PharmacoEconomics, vol. 22, no. 13, pp. 829–837, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. M. E. Hulscher, R. P. Grol, and J. W. van der Meer, “Antibiotic prescribing in hospitals: a social and behavioural scientific approach,” The Lancet Infectious Diseases, vol. 10, no. 3, pp. 167–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Drummond, M. J. Sculpher, G. W. Torrance, B. J. O'Brien, and G. L. Stoddart, Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, Oxford, UK, 2005.
  7. M. Drummond, R. Brown, A. M. Fendrick, P. Fullerton, P. Neumann, R. Taylor, and M. Barbieri, “Use of pharmacoeconomics information—report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making,” Value in Health, vol. 6, no. 4, pp. 407–416, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. A. Pauwels, A. S. Buist, P. M. A. Calverley, C. R. Jenkins, and S. S. Hurd, “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: national heart, lung, and blood institute and world health organization global initiative for chronic obstructive lung disease (GOLD): executive summary,” Respiratory Care, vol. 46, no. 8, pp. 798–825, 2001. View at Google Scholar · View at Scopus
  9. T. A. R. Seemungal, G. C. Donaldson, E. A. Paul, J. C. Bestall, D. J. Jeffries, and J. A. Wedzicha, “Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 5, pp. 1418–1422, 1998. View at Google Scholar · View at Scopus
  10. R. Sabes-Figuera, J. L. Segú, J. Puig-Junoy, and A. Torres, “Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia,” European Journal of Health Economics, vol. 9, no. 1, pp. 23–32, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. Martin, S. Quilici, T. File, J. Garau, A. Kureishi, and M. Kubin, “Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 5, pp. 977–989, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Martin, L. Moore, S. Quilici, M. Decramer, and S. Simoens, “A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium,” Current Medical Research and Opinion, vol. 24, no. 3, pp. 737–751, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. S. Simoens, N. De Corte, and G. Laekeman, “Clinical practice and costs of treating catheter-related infections with teicoplanin or vancomycin,” Pharmacy Practice, vol. 4, no. 2, pp. 68–73, 2006. View at Google Scholar · View at Scopus
  14. M. J. Wood, “The comparative efficacy and safety of teicoplanin and vancomycin,” Journal of Antimicrobial Chemotherapy, vol. 37, pp. 209–222, 1996. View at Google Scholar
  15. M. L. Zeckel, “A closer look at vancomycin, teicoplanin, and antimicrobial resistance,” Journal of Chemotherapy, vol. 9, no. 5, pp. 311–335, 1997. View at Google Scholar · View at Scopus
  16. S. Simoens and M. Decramer, “Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease,” Expert Opinion on Pharmacotherapy, vol. 8, no. 5, pp. 633–648, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. Miravitlles and A. Torres, “No more equivalence trials for antibiotics in exacerbations of COPD, please,” Chest, vol. 125, no. 3, pp. 811–813, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Miravitlles, R. Zalacain, and R. Zalacain, “Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: results of a two-year study,” Clinical Drug Investigation, vol. 23, no. 7, pp. 439–450, 2003. View at Publisher · View at Google Scholar
  19. R. Wilson, L. Allegra, G. Huchon, J. L. Izquierdo, P. Jones, T. Schaberg, and P. P. Sagnier, “Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis,” Chest, vol. 125, no. 3, pp. 953–964, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. T. M. File Jr., “Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern,” The American Journal of Medicine, vol. 117, supplement 3, pp. 39S–50S, 2004. View at Google Scholar · View at Scopus
  21. L. Moore, M. Martin, and S. Quilici, “The cost-effectiveness of targeted prescribing of antimicrobials in Canada for community-acquired pneumonia in an era of antimicrobial resistance,” Value Health, vol. 11, pp. A271–A272, 2008. View at Google Scholar
  22. M. E. Jones, R. S. Blosser-Middleton, I. A. Critchley, J. A. Karlowsky, C. Thornsberry, and D. F. Sahm, “In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001,” Clinical Microbiology and Infection, vol. 9, no. 7, pp. 590–599, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Green, A. McGeer, A. Plevneshi, and Canadian Bacterial Surveillance Network, “Trends in antimicrobial resistance in S. pneumoniae, Canada, 1993–2007,” in Proceedings of the Presentation at the 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 2008.
  24. M. R. Jacobs, D. Felmingham, and D. Felmingham, “The Alexander project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents,” Journal of Antimicrobial Chemotherapy, vol. 52, no. 2, pp. 229–246, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. Y. Valcke, CAP Guidelines: Why Differences between Belgian and American/Canadian Guidelines?2001.
  26. S. Simoens, “Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines,” Current Medical Research and Opinion, vol. 25, no. 10, pp. 2447–2457, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. Kardas, “Patient compliance with antibiotic treatment for respiratory tract infections,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 6, pp. 897–903, 2002. View at Google Scholar · View at Scopus
  28. C. Llor, K. Naberan, J. M. Cots, J. Molina, and M. Miravitlles, “Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care,” International Journal of Clinical Practice, vol. 58, no. 10, pp. 937–944, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Miravitlles, C. Murio, and T. Guerrero, “Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group,” European Respiratory Journal, vol. 17, pp. 928–933, 2001. View at Google Scholar
  30. M. Miravitlles, C. Llor, and C. Llor, “Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 99, no. 8, pp. 955–965, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. S. Simoens, “Health economics of antibiotics,” Pharmaceuticals, vol. 3, pp. 1348–1359, 2010. View at Google Scholar
  32. C. D. Hepler, “The third wave in pharmaceutical education: the clinical movement,” American Journal of Pharmaceutical Education, vol. 51, no. 4, pp. 369–385, 1987. View at Google Scholar · View at Scopus
  33. T. De Rijdt, L. Willems, and S. Simoens, “Economic effects of clinical pharmacy interventions: a literature review,” American Journal of Health-System Pharmacy, vol. 65, no. 12, pp. 1161–1172, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. P. D. Brown, “Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?” PharmacoEconomics, vol. 22, no. 7, pp. 413–420, 2004. View at Publisher · View at Google Scholar · View at Scopus